» Articles » PMID: 37174036

Experimental Murine Models for Colorectal Cancer Research

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 May 13
PMID 37174036
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is the third most prevalent malignancy worldwide and in both sexes. Numerous animal models for CRC have been established to study its biology, namely carcinogen-induced models (CIMs) and genetically engineered mouse models (GEMMs). CIMs are valuable for assessing colitis-related carcinogenesis and studying chemoprevention. On the other hand, CRC GEMMs have proven to be useful for evaluating the tumor microenvironment and systemic immune responses, which have contributed to the discovery of novel therapeutic approaches. Although metastatic disease can be induced by orthotopic injection of CRC cell lines, the resulting models are not representative of the full genetic diversity of the disease due to the limited number of cell lines suitable for this purpose. On the other hand, patient-derived xenografts (PDX) are the most reliable for preclinical drug development due to their ability to retain pathological and molecular characteristics. In this review, the authors discuss the various murine CRC models with a focus on their clinical relevance, benefits, and drawbacks. From all models discussed, murine CRC models will continue to be an important tool in advancing our understanding and treatment of this disease, but additional research is required to find a model that can correctly reflect the pathophysiology of CRC.

Citing Articles

Morphofunctional changes in the immune system in colitis-associated colorectal cancer in tolerant and susceptible to hypoxia mice.

Dzhalilova D, Silina M, Kosyreva A, Fokichev N, Makarova O PeerJ. 2025; 13:e19024.

PMID: 40028198 PMC: 11869898. DOI: 10.7717/peerj.19024.


Model systems to study tumor-microbiome interactions in early-onset colorectal cancer.

Richter K, Wrage M, Krekeler C, De Oliveira T, Conradi L, Menck K EMBO Mol Med. 2025; 17(3):395-413.

PMID: 39948421 PMC: 11903813. DOI: 10.1038/s44321-025-00198-3.


The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy.

Meyiah A, Khan F, Alfaki D, Murshed K, Raza A, Elkord E Transl Oncol. 2025; 53:102307.

PMID: 39904281 PMC: 11846588. DOI: 10.1016/j.tranon.2025.102307.


From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.


Influence of Anesthetic Techniques on Colorectal Cancer Recurrence: A Comprehensive Review.

Subhadarshini S, Taksande K Cureus. 2024; 16(8):e66521.

PMID: 39252733 PMC: 11381130. DOI: 10.7759/cureus.66521.


References
1.
Lin P, Li S, Lin H, Shih C . Germinated brown rice combined with and subsp. inhibits colorectal carcinogenesis in rats. Food Sci Nutr. 2019; 7(1):216-224. PMC: 6341155. DOI: 10.1002/fsn3.864. View

2.
Shree A, Islam J, Sultana S . Quercetin ameliorates reactive oxygen species generation, inflammation, mucus depletion, goblet disintegration, and tumor multiplicity in colon cancer: Probable role of adenomatous polyposis coli, β-catenin. Phytother Res. 2020; 35(4):2171-2184. DOI: 10.1002/ptr.6969. View

3.
Madan B, Harmston N, Nallan G, Montoya A, Faull P, Petretto E . Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. J Clin Invest. 2018; 128(12):5620-5633. PMC: 6264740. DOI: 10.1172/JCI122383. View

4.
Zhou H, Liu Z, Wang Y, Wen X, Amador E, Yuan L . Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduct Target Ther. 2022; 7(1):70. PMC: 8897452. DOI: 10.1038/s41392-022-00922-2. View

5.
Choi S, Huang A, Letterio J, Kim B . Smad4-deficient T cells promote colitis-associated colon cancer an IFN-γ-dependent suppression of 15-hydroxyprostaglandin dehydrogenase. Front Immunol. 2022; 13:932412. PMC: 9420841. DOI: 10.3389/fimmu.2022.932412. View